Abstract
This phase I, double-blind, randomized, placebo-controlled study evaluated the safety of single and multiple (daily for 7 days) subcutaneous administrations of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy human volunteers at seven doses, ranging from 3 to 500 μg/kg/day. No serious or life-threatening adverse events occurred. The most frequently recorded adverse effects were mild injection-site pain, diarrhea, and elevation of liver function tests. No change in neurologic function was noted with these dosing regimens. We conclude that r-metHuNT3 is safe and well tolerated in the dosages used in this study.
Original language | English (US) |
---|---|
Pages (from-to) | 189-192 |
Number of pages | 4 |
Journal | Muscle and Nerve |
Volume | 23 |
Issue number | 2 |
DOIs | |
State | Published - 2000 |
Keywords
- NT3
- Neurotrophins
- Peripheral neuropathy
- Toxic neuropathy
ASJC Scopus subject areas
- Physiology
- Clinical Neurology
- Cellular and Molecular Neuroscience
- Physiology (medical)